Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
82 hedge funds and large institutions have $79.4M invested in Navidea Biopharmaceuticals Inc. in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 87 → 82 (-5)
14% less capital invested
Capital invested by funds: $92.8M → $79.4M (-$13.4M)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
97% less call options, than puts
Call options by funds: $286K | Put options by funds: $9.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.28M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.68M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$975K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$513K |
| 5 |
State Street
Boston,
Massachusetts
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Platinum Management
New York
|
-$5.33M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$933K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$406K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$216K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$178K |
NAVB Hedge Fund Activity: Q1 2015 in Review
82 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2015, worth a combined $79.4M — down 14% from $92.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NAVB and 8 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was Goldman Sachs, adding an estimated $5.28M. The largest seller was Platinum Management, cutting an estimated $5.33M.
- 82 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2015, down from 87 in Q4 2014.
- Funds reported $79.4M of Navidea Biopharmaceuticals Inc. stock for Q1 2015, down 14% quarter-over-quarter.
- 8 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2015 and 13 closed out, a net change of -5 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2015 was Goldman Sachs, an estimated $5.28M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2015 was Platinum Management, an estimated $5.33M sold.
Based on aggregated 13F filings for Q1 2015.